Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease

NCT02675465 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.

NCT NCT02675465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02675465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Lead sponsor
Amicus Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2016
Completion date
August 22, 2024
Enrollment
29 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

pompe disease